- Home
- RDHL vs PCSA Comparison
RDHL vs PCSA Comparison
Compare RDHL & PCSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDHL
- PCSA
- Stock Information
- Founded
- RDHL 2009
- PCSA 2011
- Country
- RDHL Israel
- PCSA United States
- Employees
- RDHL N/A
- PCSA N/A
- Industry
- RDHL Biotechnology: Pharmaceutical Preparations
- PCSA Biotechnology: Pharmaceutical Preparations
- Sector
- RDHL Health Care
- PCSA Health Care
- Exchange
- RDHL Nasdaq
- PCSA Nasdaq
- Market Cap
- RDHL 3.9M
- PCSA 3.3M
- IPO Year
- RDHL N/A
- PCSA N/A
- Fundamental
- Price
- RDHL $1.51
- PCSA $0.19
- Analyst Decision
- RDHL
- PCSA Strong Buy
- Analyst Count
- RDHL 0
- PCSA 1
- Target Price
- RDHL N/A
- PCSA $1.00
- AVG Volume (30 Days)
- RDHL 88.5K
- PCSA 2.3M
- Earning Date
- RDHL 09-05-2025
- PCSA 10-29-2025
- Dividend Yield
- RDHL N/A
- PCSA N/A
- EPS Growth
- RDHL N/A
- PCSA N/A
- EPS
- RDHL N/A
- PCSA N/A
- Revenue
- RDHL $9,550,000.00
- PCSA N/A
- Revenue This Year
- RDHL $381.91
- PCSA N/A
- Revenue Next Year
- RDHL N/A
- PCSA N/A
- P/E Ratio
- RDHL N/A
- PCSA N/A
- Revenue Growth
- RDHL 157.62
- PCSA N/A
- 52 Week Low
- RDHL $1.06
- PCSA $0.15
- 52 Week High
- RDHL $11.70
- PCSA $1.50
- Technical
- Relative Strength Index (RSI)
- RDHL 54.23
- PCSA 42.95
- Support Level
- RDHL $1.22
- PCSA $0.16
- Resistance Level
- RDHL $1.60
- PCSA $0.20
- Average True Range (ATR)
- RDHL 0.08
- PCSA 0.02
- MACD
- RDHL 0.04
- PCSA 0.00
- Stochastic Oscillator
- RDHL 76.32
- PCSA 44.66
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.
About PCSA Processa Pharmaceuticals Inc.
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).